Biogen Inc. (BIIB) Deep Dive Video

Biogen’s “post-MS” reset is hitting an inflection point—Alzheimer’s, rare disease, and SYFOVRE aim to replace legacy erosion, with the LEQEMBI subcutaneous decision as the pivotal near-term catalyst.